The BioPharm Brief: Antibodies, Alliances, and Acquisitions

Jul 27, 07:00 PM
Headliner
Share
Subscribe

Today's podcast episode highlights three stories shaping the future of antibody therapeutics, from a next-generation bispecific ADC advancing toward the clinic, to a new biologics innovation consortium in China, to a major acquisition expanding an autoimmune pipeline.

Share
Subscribe
Next
The BioPharm Brief: Bispecifics, Breakthroughs, and Business Decisions
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief